Search details
1.
Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial.
Lancet
; 400(10369): 2210-2220, 2022 12 17.
Article
in English
| MEDLINE | ID: mdl-36528376
2.
A Neurofunctional Domains Approach to Evaluate D1/D5 Dopamine Receptor Partial Agonism on Cognition and Motivation in Healthy Volunteers With Low Working Memory Capacity.
Int J Neuropsychopharmacol
; 23(5): 287-299, 2020 05 27.
Article
in English
| MEDLINE | ID: mdl-32055822
3.
Impact of Phase 1 study design on estimation of QT interval prolongation risk using exposure-response analysis.
J Pharmacokinet Pharmacodyn
; 46(6): 605-616, 2019 Dec.
Article
in English
| MEDLINE | ID: mdl-31664592
4.
Estimation of Circulating Drug Metabolite Exposure in Human Using In Vitro Data and Physiologically Based Pharmacokinetic Modeling: Example of a High Metabolite/Parent Drug Ratio.
Drug Metab Dispos
; 46(2): 89-99, 2018 02.
Article
in English
| MEDLINE | ID: mdl-29150544
5.
Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson's Disease following Oral Administration.
Neurodegener Dis
; 18(5-6): 262-269, 2018.
Article
in English
| MEDLINE | ID: mdl-30453303
6.
Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's Disease.
CNS Neurol Disord Drug Targets
; 23(4): 476-487, 2024.
Article
in English
| MEDLINE | ID: mdl-36999711
7.
PET imaging of M4 muscarinic acetylcholine receptors in rhesus macaques using [11C]MK-6884: Quantification with kinetic modeling and receptor occupancy by CVL-231 (emraclidine), a novel positive allosteric modulator.
J Cereb Blood Flow Metab
; : 271678X241238820, 2024 Mar 13.
Article
in English
| MEDLINE | ID: mdl-38477292
8.
Dopamine agonists in Parkinson's disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment.
Clin Park Relat Disord
; 9: 100212, 2023.
Article
in English
| MEDLINE | ID: mdl-37497384
9.
Dopamine D1 Agonists: First Potential Treatment for Late-Stage Parkinson's Disease.
Biomolecules
; 13(5)2023 05 12.
Article
in English
| MEDLINE | ID: mdl-37238699
10.
Parkinson disease among patients treated for benign prostatic hyperplasia with α1 adrenergic receptor antagonists.
J Clin Invest
; 131(11)2021 06 01.
Article
in English
| MEDLINE | ID: mdl-33822767
11.
PF-06649751 efficacy and safety in early Parkinson's disease: a randomized, placebo-controlled trial.
Ther Adv Neurol Disord
; 13: 1756286420911296, 2020.
Article
in English
| MEDLINE | ID: mdl-32201505
12.
Dopaminergic D1 Receptor Stimulation Affects Effort and Risk Preferences.
Biol Psychiatry
; 87(7): 678-685, 2020 04 01.
Article
in English
| MEDLINE | ID: mdl-31668477
13.
Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data.
Clin Pharmacol Ther
; 107(4): 796-805, 2020 04.
Article
in English
| MEDLINE | ID: mdl-31955409
14.
The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson's Disease: A Feasibility Study.
J Parkinsons Dis
; 10(4): 1515-1527, 2020.
Article
in English
| MEDLINE | ID: mdl-32986682
15.
A novel approach to evaluate the pharmacodynamics of a selective dopamine D1/D5 receptor partial agonist (PF-06412562) in patients with stable schizophrenia.
J Psychopharmacol
; 33(10): 1237-1247, 2019 10.
Article
in English
| MEDLINE | ID: mdl-31264510
16.
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson's Disease.
Clin Drug Investig
; 38(6): 509-517, 2018 Jun.
Article
in English
| MEDLINE | ID: mdl-29478239
17.
Phase 1 Parkinson's Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated.
Neurol Ther
; 7(2): 307-319, 2018 Dec.
Article
in English
| MEDLINE | ID: mdl-30361858
18.
Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats.
Int J Pharm
; 336(2): 233-40, 2007 May 24.
Article
in English
| MEDLINE | ID: mdl-17207946
19.
Controlled delivery of ganciclovir to the retina with drug-loaded Poly(d,L-lactide-co-glycolide) (PLGA) microspheres dispersed in PLGA-PEG-PLGA Gel: a novel intravitreal delivery system for the treatment of cytomegalovirus retinitis.
J Ocul Pharmacol Ther
; 23(3): 264-74, 2007 Jun.
Article
in English
| MEDLINE | ID: mdl-17593010
20.
Studying the Progression of Amyloid Pathology and Its Therapy Using Translational Longitudinal Model of Accumulation and Distribution of Amyloid Beta.
CPT Pharmacometrics Syst Pharmacol
; 6(10): 676-685, 2017 10.
Article
in English
| MEDLINE | ID: mdl-28913897